Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 11/2010

01-11-2010 | Original Paper

MGMT gene promoter methylation in pediatric glioblastomas

Authors: Arti Srivastava, Ayushi Jain, Prerana Jha, Vaishali Suri, Mehar Chand Sharma, Supriya Mallick, Tarun Puri, Deepak Kumar Gupta, Aditya Gupta, Chitra Sarkar

Published in: Child's Nervous System | Issue 11/2010

Login to get access

Abstract

Purpose

Relatively few studies have been performed on molecular properties of pediatric glioblastoma multiforme (GBM). Methylation of DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) promoter region has been associated with favorable prognosis and prolonged survival in adult GBM patients treated with temozolomide (TMZ). We explored the frequency of MGMT gene promoter methylation in pediatric glioblastomas and compared it with the known molecular alterations in p53.

Methods

Twenty pediatric GBM cases were selected. MGMT promoter methylation was assessed by methylation specific PCR. p53 expression was determined by immunohistochemistry.

Results

MGMT gene promoter methylation was observed in 50% of pediatric glioblastomas. p53 protein expression was detected in 60% of cases. Seventy percent of cases with methylated MGMT promoter were p53 immunopositive.

Conclusions

The frequency of MGMT gene promoter methylation in pediatric GBMs was similar to adult GBM patients. The pediatric GBMs should also be investigated for MGMT promoter methylation to identify a subset of patients likely to benefit from TMZ therapy. p53 protein overexpression was more common in pediatric primary GBMs. To the best of our knowledge this is only the second study on MGMT gene promoter methylation status in pediatric GBMs.
Literature
1.
Nicholson HS, Kretschmar CS, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. Cancer 110:1542–1549CrossRefPubMed
2.
3.
Bleyer WA (1999) Epidemiological impact of children with brain tumors. Childs Nerv Syst 15:758–763CrossRefPubMed
4.
Cheng Y, Ng HK, Zhang SF et al (1999) Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 30:1284–1290CrossRefPubMed
5.
Ganigi PM, Santosh V, Anandh B, Chandramouli BA (2005) Expression of p53, EGFR, pRb and bcl-2 protein in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg 41:292–299CrossRefPubMed
6.
Suri V, Das P, Jain A et al (2009) Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 11:274–280CrossRefPubMed
7.
Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomas. Pediatr Blood Cancer 48:403–407CrossRefPubMed
8.
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
9.
Yung WK, Albright RE, Olsen J (2000) A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 85:588–593CrossRef
10.
Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266CrossRefPubMed
11.
Gilbert MR, Friedman HS, Kuttesch JF et al (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 4:261–267PubMed
12.
Erickson LC, Laurent G, Sharkey NA, Kohn KW (1980) DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 288:727–729CrossRefPubMed
13.
Ludlum DB (1990) DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 233:117–126PubMed
14.
Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167–223CrossRefPubMed
15.
Qian XC, Brent TP (1997) Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57:3672–3677PubMed
16.
Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797PubMed
17.
Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167–5174CrossRefPubMed
18.
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 52:997–1003CrossRef
19.
Esteller M, Gracia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354CrossRefPubMed
20.
Eoli M, Menghi F, Bruzzone MG et al (2007) Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 13:2606–2613CrossRefPubMed
21.
Friedman HS, McLendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMed
22.
Hegi ME, Diserens A-C, Godard S et al (2004) Clinical trial substantiates the predictive value of O6 methyl guanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874CrossRefPubMed
23.
Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumors of central nervous system, 4th edn. IARC, Lyon, pp 33–49
24.
Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933–4938CrossRefPubMed
25.
Broniscer A, Iacono L, Chintagumpala M et al (2005) Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 103:133–139CrossRefPubMed
26.
Broniscer A, Chintagumpala M, Fouladi M et al (2006) Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 76:313–319CrossRefPubMed
27.
Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G (2004) Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J Cancer 91:425–429CrossRefPubMed
28.
Barone G, Maurizi P, Tamburrini G, Riccardi R (2006) Role of temozolomide in pediatric brain tumors. Childs Nerv Syst 22:652–661CrossRefPubMed
29.
Jakacki RI, Yates A, Blaney SM et al (2008) A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol 10:569–576CrossRefPubMed
30.
Lashford LS, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup study. J Clin Oncol 20:4684–4691CrossRefPubMed
31.
Estlin EJ, Lashford L, Ablett S et al (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 78:652–661PubMed
32.
Loh KC, Willert J, Meltzer H et al (2005) Temozolomide and radiation for aggressive pediatric central nervous system malignancies. J Pediatr Hematol Oncol 27:254–258CrossRefPubMed
33.
Belanich M, Pastor M, Randall T et al (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56:783–788PubMed
34.
Hotta T, Saito Y, Fujita H et al (1994) O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 21:135–140CrossRefPubMed
35.
Wiewrodt D, Nagel G, Dreimuller N, Hundsberger T, Perneczky A, Kaina B (2008) MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer 122:1391–1399CrossRefPubMed
36.
Pollack IF, Hamilton RL, Sobol RW et al (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431–3437CrossRefPubMed
37.
Stupp R, Hegi ME (2007) Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol 25:1459–1460CrossRefPubMed
38.
Everhard S, Kaloshi G, Crinière E et al (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740–743CrossRefPubMed
39.
Sure U, Ruedi D, Tachibana O et al (1997) Determination of p53 mutation, EGFR overexpression and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56:782–789PubMed
40.
Bhattacharjee MB, Bruner JM (1997) p53 protein in pediatric malignant astrocytoma. A study of 21 patients. J Neurooncol 32:225–233CrossRefPubMed
41.
Pollack IF, Finkelstein SD, Woods J et al (2002) Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346:420–427CrossRefPubMed
Metadata
Title
MGMT gene promoter methylation in pediatric glioblastomas
Authors
Arti Srivastava
Ayushi Jain
Prerana Jha
Vaishali Suri
Mehar Chand Sharma
Supriya Mallick
Tarun Puri
Deepak Kumar Gupta
Aditya Gupta
Chitra Sarkar
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Child's Nervous System / Issue 11/2010
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-010-1214-y

Other articles of this Issue 11/2010

Child's Nervous System 11/2010 Go to the issue

Original Paper

Severe traumatic brain injury in children—a single center experience regarding therapy and long-term outcome

Review Paper

Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges

Letter to the Editor

Posterior fossa tumors in children with neurofibromatosis type 1 (NF1)

Letter to the Editor

Reply to Dr H Gardner

Original Paper

Surgical morbidity and mortality of pediatric brain tumors: a single center audit

Original Paper

Safety and efficacy of continuous morphine infusions following pediatric cranial surgery in a surgical ward setting